Dr. Bérard, PhD, FCAHS, FISPE, has cross-training in epidemiology and genetics from McGill University, Harvard Medical School, and Stanford University. She is a full professor of perinatal epidemiology at the Faculty of Pharmacy of the University of Montreal, and CHU Sainte-Justine in Montreal; and an adjunct professor at the Faculty of Medicine of the Université Claude Bernard in Lyon, France. Dr. Bérard holds a Canada Research Chair Tier 1 on Medications and Pregnancy; and the University of Montreal’s Louis-Boivin research chair on "Medications, pregnancy and lactation". Anick Bérard is also director of the Research Unit on Medications and Pregnancy at the CHU Sainte-Justine; director of the Réseau québécois de recherche sur les médicaments of the Fonds de recherche du Québec – Santé (FRQS); fellow of the International Society of Pharmacoepidemiology; and a voting member of the Society for Birth Defects Research and Prevention. Anick Bérard is the principal investigator of the i) Pan-Canadian CONCEPTION Study – COVID-19 and Pregnancy, ii) Quebec Pregnancy-Child Cohort, iii) Canadian Mother-Child Cohort (CAMCCO) Active Surveillance Initiative, iv) Canadian Mother-Child Collaborative Training Platform (CAMCCO-L), v) AMerican PREGNANcy/Child CohorT (AM-PREGNANT), and vi) French Nationwide Pregnancy Cohort, PregMed-France. Dr. Bérard has published over 500 scientific papers, abstracts and patents, and has obtained over 29 million dollars in funding from the Canadian Institutes of Health Research (CIHR), the Canada Foundation for Innovation (CFI), and the FRQS as principal investigator. She recently received a Most Distinguished Scientist Award from the Society for Birth Defects Research and Prevention for her work on antidepressants, maternal depression, and pregnancy.